JERUSALEM--(BUSINESS WIRE)--Dec. 10, 2004--Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that the U.S. Food and Drug Administration has granted tentative approval for the Company’s ANDA for Oxycodone Hydrochloride Extended Release Tablets, 10 mg, 20 mg, and 40 mg. Final approval is subject to the expiration of any applicable exclusivity period enjoyed by another ANDA filer for the same product.
